Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) insider Jeffrey Arcara purchased 3,000 shares of Corvus Pharmaceuticals stock in a transaction on Wednesday, November 11th. The stock was bought at an average price of $11.46 per share, with a total value of $34,380.00. Following the completion of the acquisition, the insider directly owned 3,000 shares of the company’s stock, valued at approximately $34,380. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jeffrey Arcara also recently made the following trade(s):
- On Friday, November 13th, Jeffrey Arcara purchased 1,003 shares of Corvus Pharmaceuticals stock. The stock was bought at an average cost of $10.54 per share, with a total value of $10,571.62.
- On Thursday, November 12th, Jeffrey Arcara acquired 497 shares of Corvus Pharmaceuticals stock. The shares were bought at an average price of $11.12 per share, for a total transaction of $5,526.64.
Corvus Pharmaceuticals Stock Performance
Shares of NASDAQ CRVS opened at $10.64 on Monday. The firm has a market capitalization of $897.48 million, a P/E ratio of -14.99 and a beta of 1.57. The firm’s 50-day moving average price is $11.18 and its 200-day moving average price is $14.04. Corvus Pharmaceuticals, Inc. has a 1-year low of $6.39 and a 1-year high of $26.95.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Equities research analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.81 EPS for the current year.
Institutional Trading of Corvus Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at about $106,654,000. Commodore Capital LP bought a new position in shares of Corvus Pharmaceuticals during the 1st quarter worth approximately $33,045,000. Perceptive Advisors LLC lifted its position in shares of Corvus Pharmaceuticals by 231.1% during the 1st quarter. Perceptive Advisors LLC now owns 2,292,441 shares of the company’s stock worth $33,538,000 after buying an additional 1,600,000 shares in the last quarter. Fisher Asset Management LLC purchased a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth approximately $11,988,000. Finally, Bank of America Corp DE purchased a new position in shares of Corvus Pharmaceuticals in the 2nd quarter worth approximately $11,322,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research report on Monday, October 26th. Ladenburg Thalmann & Co. Inc. upgraded Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th. Mizuho set a $27.00 price objective on Corvus Pharmaceuticals in a report on Thursday, October 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $32.83.
Read Our Latest Report on CRVS
Recent Corvus Pharmaceuticals Headlines
Investors following CRVS have been watching these headlines:
- Positive Sentiment: A Globe and Mail headline includes Corvus among healthcare stocks analysts are bullish on, though the article details provided do not specify a rating or price target. Analysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), Achieve Life Sciences (QUIT)
- Negative Sentiment: HC Wainwright cut estimates across multiple periods. It now expects a $1.04-per-share loss in 2027, versus its prior $0.80 loss estimate, and a $0.90 loss in 2028, versus $0.37 previously. It also reduced its 2029 forecast from near breakeven to a $0.43 loss and lowered its 2030 profit estimate to $0.45 from $0.67. The revisions suggest a slower improvement in earnings and could weigh on investor sentiment. HC Wainwright earnings estimate updates
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.
Recommended Stories
- Five stocks we like better than Corvus Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
